How Many mg Is 100 Units of Tirzepatide — and Why the Question Contains a Misconception

The myth: tirzepatide doses can be converted to units like insulin

This is the most common misconception sitting beneath this query, and it is understandable. Insulin has been the dominant injectable medicine in home use for decades, and many people who now start tirzepatide have previously used insulin or know someone who has. Insulin is measured in international units (IU) because its biological potency varies between formulations; a unit is a standardised measure of effect, not a fixed weight of drug. Standard U-100 insulin contains 100 units per millilitre, which is why "100 units" is a familiar number for anyone in that world.

Tirzepatide works differently. It is a synthetic peptide with a fixed molecular structure, and its dose is simply a mass, milligrams of the molecule per injection. There is no unit-based conversion because the concept does not apply. 100 units of tirzepatide is, in a practical sense, a meaningless phrase. It is not a low dose, a high dose, or an off-label dose. It is not a dose at all.

If you have seen "100 units" on a syringe scale in a social-media post or a forum thread about Mounjaro, the most likely explanation is that the person was either using insulin syringes to draw up a compounded preparation (not the licensed Mounjaro KwikPen) or was simply misreading the measurement system. Neither scenario describes how licensed tirzepatide is prescribed or dispensed in the UK.

What the actual milligram doses of tirzepatide mean in practice

Licensed tirzepatide in the UK (sold as Mounjaro by Eli Lilly) comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each strength is a pre-filled KwikPen containing four weekly doses. The pen injects a fixed volume; the patient does not see a syringe scale or draw up any liquid. There is no user-facing measurement step at all. You press the pen against the skin, press the button, hold for ten seconds, done. The pen that lives in the fridge door between weekly doses is the complete, self-contained system.

Treatment typically starts at 2.5 mg. That is not the dose at which most therapeutic effect is expected; it is a tolerability phase designed to let the body adjust before the prescriber considers whether to step up. The progression through doses (and the timing of any increase) is a clinical decision, not a schedule patients move through automatically. Our clinical team reviews each patient's progress before any repeat, which means dose changes are assessed individually rather than applied as a rule.

For a closer look at how a specific lower dose translates if someone has encountered unit-based language elsewhere, the page on 10 units of tirzepatide in mg terms addresses the same underlying confusion at a different starting number. If you are moving onto the second maintenance strength, the page covering what 5 mg of tirzepatide looks like in unit terms works through that same confusion for that specific dose. Similarly, questions about how 2.5 mg relates to units come up regularly and follow the same logic: the answer is that the framing does not apply to licensed tirzepatide.

Why this mix-up can carry real risk

Medication errors involving the wrong measurement system for injectables are a well-documented patient safety concern. The National Reporting and Learning System has historically flagged insulin-unit errors as a high-harm category. Tirzepatide is not insulin, but the error pattern is worth understanding, someone familiar with U-100 insulin syringes might, in theory, try to apply that logic to a GLP-1 medicine, particularly if they are sourcing a compounded or unlicensed product that does not come in a pre-filled pen.

This is one of several reasons why the MHRA has issued public warnings about purchasing weight-loss injectable medicines from unverified sources. Licensed Mounjaro comes pre-filled. There is no dose to measure. If a product described as tirzepatide requires the user to draw up a volume using a syringe calibrated in units, it is not the licensed medicine.

The cost context around tirzepatide is relevant here too. Following Eli Lilly's UK list-price changes in September 2025 (covered in detail on the Mounjaro price increase page) private costs per pen rose significantly. That price pressure has driven some people towards cheaper, unverified sources, which are more likely to involve non-standard presentations. The licensed route, through a clinically supervised Mounjaro service, keeps dose and format unambiguous.

Getting the right dose for you is a clinical conversation, not a conversion sum

Even among the licensed milligram doses, the question of which strength is appropriate for a specific person is not something a chart or a calculator can answer. Prescribers look at starting weight, how the body has responded to previous doses, what side effects (if any) have occurred, and whether the rate of weight change is in a reasonable range. People stepping up to the third maintenance strength sometimes find the page on how many units 7.5 mg of tirzepatide corresponds to useful for understanding why the unit framing still does not apply at that stage. The NICE appraisal of tirzepatide (TA1026) sets out the clinical framework within which treatment is recommended, including thresholds for continuing or reviewing.

If you are already on treatment and have a question about your current dose (whether a dose increase is overdue, whether a missed injection changes the picture, or how your progress compares to trial data) those are questions for your prescriber, not for a unit-to-milligram lookup. Our frequently asked questions covers a number of common dose-related queries, and our aftercare team is available seven days a week for patients already on treatment.

For anyone earlier in the process, exploring the range of weight-loss treatments available through nume is a reasonable starting point before a consultation.